Key Sessions
Alexandra Zemp
While Biotech Financing Is Accelerating, Early-Stage Innovation Exceeds Financing Opportunities. A Discussion on the Potential Impact To the Broader Industry
McKinsey & Co.
Maha Radhakrishnan
Life Science Executives in 2024: Evaluating a Critical Year of Shifting Approvals, Rejuvenated Funding, and Strategic Deals for Future Success
Sofinnova Investments
Daniela Begolo
From Promise to Proof: Powering Post-Series A Growth in Biotech
EQT Life Sciences
Marta Lesko
Unique Partnering Strategies: Bridging Biotech and Pharma for Enhanced Collaboration
Merck Group